David Hung bought $821K of Nuvation Bio (NUVB)
Executed Apr 4 2025, disclosed Apr 8 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Apr 8 2025), the stock returned +9.1% (delay-adjusted); from the execution session (Apr 4 2025), +40.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
David Hung (PRESIDENT AND CEO) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in Nuvation Bio Inc. (NUVB). Across 2 priced purchase filings, the average 21-session return was +37.6% from execution and +21.0% from disclosure (delay-adjusted; derived). The largest single filing was $895K of NUVB (500,000 sh × $1.79, as filed), executed Jun 16 2025.
Healthcare · Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→500,000 sh × $1.79
Exec Jun 16 2025
Filed Jun 18 2025 · 5:30 PM ET